Misplaced Pages

This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 06:32, 21 October 2011 (Updating {{drugbox}} (changes to verified fields - updated 'ChEBI_Ref', 'CAS_number_Ref') per Chem/Drugbox validation (report errors or bugs)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Olopatadine

Clinical data
Trade names	Patanol
AHFS/Drugs.com	Monograph
MedlinePlus	a602025
Pregnancy category	C
Routes of administration	Ophthalmic, intranasal, oral
ATC code	S01GX09 (WHO) R01AC08 (WHO)
Pharmacokinetic data
Elimination half-life	3 hours
Identifiers
IUPAC name {(11Z)-11--6,11- dihydrodibenzooxepin-2-yl}acetic acid
CAS Number	113806-05-6
PubChem CID	5281071
DrugBank	APRD00310
ChemSpider	4444528
UNII	D27V6190PM
KEGG	D08293
ChEMBL	ChEMBL1189432
CompTox Dashboard (EPA)	DTXSID20150556
Chemical and physical data
Formula	C21H23NO3
Molar mass	337.412 g/mol g·mol
3D model (JSmol)	Interactive image
SMILES O=C(O)Cc2ccc1OCc3c(C(\c1c2)=C\CCN(C)C)cccc3
InChI InChI=1S/C21H23NO3/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24)/b18-8- Key:JBIMVDZLSHOPLA-LSCVHKIXSA-N
(what is this?)  (verify)

Olopatadine hydrochloride is an antihistamine (as well as anticholinergic) and mast cell stabilizer, sold as a prescription eye drop (0.2% solution, Pataday (or Patanol S in some countries), manufactured by Alcon). It is used to treat itching associated with allergic conjunctivitis (eye allergies). Olopatadine hydrochloride 0.1% is sold as Patanol (or Opatanol in some countries). A nasal spray formulation is sold as Patanase, which was approved by the FDA on April 15, 2008. It is also available as an oral tablet in Japan under the tradename Allelock, manufactured by Kyowa Hakko Kogyo.

It should not be used to treat irritation caused by contact lenses. The usual dose for Patanol is 1 drop in each affected eye 2 times per day, with 6 to 8 hours between doses.

Its side effects may include headaches (7% of occurrence) burning and stinging (5%), dry eye, foreign body sensation, hyperemia, keratitis, lid edema, pruritus, asthenia, cold syndrome, pharyngitis, rhinitis, sinusitis, and taste perversion.

Olopatadine was developed by Kyowa Hakko Kogyo.

References

1. Drugs.com, Alcon's Patanase Nasal Spray Approved by FDA for Treatment of Nasal Allergy Symptoms
2. Kyowa Hakko Kogyo Co., Ltd. (2007). "ALLELOCK Tablets 2.5 & ALLELOCK Tablets 5 (English)" (PDF). Retrieved 2008-08-10.
3. Kyowa Hakko Kogyo Co., Ltd. (2002). "Company History". Company Information. Kyowa Hakko Kogyo Co., Ltd. Retrieved 16 September 2010.

External links

• Pataday website
• Patanase website
• Olopatadine Ophthalmic via MedlinePlus

This drug article relating to the respiratory system is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Oxepines
• Carboxylic acids
• H1 receptor antagonists
• Amines
• Respiratory system drug stubs